CN105998015A - Application of PPARdelta (Peroxisome proliferator-activated receptor delta) selective antagonist in preparation of drugs for treating psoriasis - Google Patents
Application of PPARdelta (Peroxisome proliferator-activated receptor delta) selective antagonist in preparation of drugs for treating psoriasis Download PDFInfo
- Publication number
- CN105998015A CN105998015A CN201610344938.4A CN201610344938A CN105998015A CN 105998015 A CN105998015 A CN 105998015A CN 201610344938 A CN201610344938 A CN 201610344938A CN 105998015 A CN105998015 A CN 105998015A
- Authority
- CN
- China
- Prior art keywords
- ppar
- selective antagonist
- application
- medicine
- gsk3787
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to the technical field of medicine, in particular to application of a PPARdelta (Peroxisome proliferator-activated receptor delta) selective antagonist in preparation of drugs for treating psoriasis. According to the invention, the PPARdelta selective antagonist is used for treating mice psoriasis-like inflammation caused by IMQ, and the result shows that the curative effect of GSK3787 is more significant. According to the invention, the application of the PPARdelta selective antagonist in the treatment of skin diseases is developed, meanwhile the mechanical application of the GSK3787 is extended to the skin field, and a new treatment measure is provided for clinical anti-psoriasis treatment.
Description
Technical field
The present invention relates to pharmaceutical technology field, specifically, be the new of a kind of PPAR δ selective antagonist
Medical usage.
Background technology
Psoriasis is a kind of spontaneous immune disease chronic, struvite, probably affects this whole world about 2-3%'s
Population, many factors can induce psoriatic generation.Psoriasis has two major features: be difficult to recovery from illness with easy
Recurrence, this brings great inconvenience to psoriatic treatment.Originally, it is believed that psoriasis is skin
Hyper-proliferative causes.Later, along with the understanding to TH1 cell and IFN-γ, researcher thinks again silver-colored
Bits are sick cell-mediated by Th1.Afterwards, sight is gradually focused on TH17 cell by people, it is believed that it
In psoriatic development, also play highly important effect, subsequently for TH17 cell and
In the clinical drug therapy research of relevant cell factor, also demonstrate that the status of TH17 cell.
Horn cell (Keratinocytes, KCs) can secrete substantial amounts of Chemokines such as because of it
CXCL-1/2/8, CCL-20 etc., these chemotactic factors can chemotactic such as CD11c+ dendritic cell and
CCR6+TH17 cell, thus KCs is considered to occupy critically important status in psoriatic development, this
Outward, KCs can also secrete such as S100A7, and 8,9, these antibacterial proteins have accounted for one in psoriatic morbidity
Fixed effect.Along with to psoriasis research and understanding go deep into, researchers have become increasingly aware of psoriasis its
It is a kind of spontaneous immune disease jointly mediated by immunocyte and KCs in fact.
Peroxisome proliferator-activated receptor δ (PPAR δ) is substantial amounts of to be present in colon and skin,
Its activation needs form dimer with retinoic acid receptor X α (retinoid X receptor α, RXR α).
There is dispute in PPAR δ effect in onset of psoriasis, is primarily due to following reason: on the one hand some grinds
The person of studying carefully thinks that the expression of PPAR δ is caused by transcription factor AP-1.On the other hand, other researcheres
Think that PPAR δ occupies mastery reaction in psoriasis and is primarily due to: first, PPAR δ can be done
Disturb element the induced generation of IFN-a, and the existence of IFN-a is a psoriatic feature.Secondly, PPAR δ
Some downstream genes such as CD36 and FABP5 also high expressed, indicate PPAR δ in psoriatic lesion
Also it is to activate.The endogenic ligand of the 3rd, PPAR δ such as 8-, 12-, 15-HETE are at psoriatic lesion
Middle accumulation.Additionally, PPAR δ can improve the survival of T cell in psoriatic lesion by ERK2 path.
In the recent period, Romanowska, M. et al. confirm that PPAR δ selective agonist can induce PPAR δ to turn
DNA murine produce psoriasiform symptom (Romanowska M, Reilly L, Palmer CN,
Gustafsson MC,&Foerster J(2010)Activation of PPARbeta/delta causes a
psoriasis-like skin disease in vivo.PloS one 5(3):e9701).Based on the above reason,
PPAR δ is considered to occupy an important position in psoriasis.But about a kind of PPAR δ selectivity antagonism
Agent is treated psoriatic application and be yet there are no report.
IFN-γ is TH1 cytokines, and it is high expressed in psoriasis, the research of getting up early confirm its
Psoriatic development serves critically important effect, but is shown by the research of suppression IFN-γ effect,
Block IFN-γ and can not play the psoriatic effect for the treatment of.In addition, PPAR δ and cardiovascular disease
As atherosis grade is correlated with, but in current clinic, PPAR delta antagonist is for atherosis treatment curative effect
Inconspicuous.Finally, the effect of PPAR δ there is also a lot of disputes, as the rush of horn cell is bred by it
Effect and differentiation.Therefore, the present invention utilizes PPAR δ specific antagonists to investigate it to psoriasis
Therapeutical effect.
Summary of the invention
It is an object of the invention to provide the new medical usage of PPAR δ selective antagonist, specifically
The application in preparation treatment psoriasis of the PPAR δ selective antagonist.
A first aspect of the present invention, it is provided that PPAR δ selective antagonist is in preparation treatment psoriasis
Application.
Described medicine can be external preparation, as Emulsion, ointment, rubber plaster, colloid, membrane,
Tincture, medicated wine, distillate medicinal water, sponginum, ionophore, or cutaneous permeable agent etc..
Preferably, described medicine is gel preparation or ointment formulation.
Described pharmaceutical pack contains one or more PPAR δ selective antagonists.
Described medicine is using a kind of PPAR δ selective antagonist as sole active agent, or comprises two
Plant above PPAR δ selective antagonist, and acceptable adjuvant or carrier on other drug.
Preferably, described PPAR δ selective antagonist is GSK3787.
It is furthermore preferred that described medicine is using GSK3787 as sole active composition.In described medicine
The concentration of GSK3787 is 50uM.
A second aspect of the present invention, it is provided that one treats psoriatic medicine, the psoriatic medicine of described treatment
The active component of thing is PPAR δ selective antagonist.
The described active component treating psoriatic medicine is GSK3787.
Preferably, the psoriatic medicine of described treatment is using GSK3787 as sole active composition.Institute
The concentration of GSK3787 in psoriatic medicine for the treatment of stated is 5uM.
A third aspect of the present invention, it is provided that PPAR δ application in screening treatment psoriasis, described
Medicine be PPAR delta antagonist or inhibitor.Preferably, described medicine is that PPAR δ selectivity is short of money
Anti-agent.
The present invention has excavated the medical application of PPAR δ selective antagonist, has opened up a new application neck
Territory.The selective antagonist of present invention PPAR δ treats the mice psoriasiform inflammation that IMQ causes,
Result display GSK3787 comparitive study is notable.The present invention develops PPAR δ selective antagonist treatment skin
The purposes that skin is sick, has also been extended to dermal region by the pharmaceutical usage of GSK3787, for clinical anti-silver simultaneously
Bits disease treatment provides new treatment means.
Accompanying drawing explanation
Fig. 1 .PPAR δ expression in Healthy People skin and psoriatic lesion, left side is Healthy People skin,
Right side is psoriasis people's skin lesion.
Fig. 2 .PPAR δ expression in WT mice and IMQ mouse skin, left side is the little Corium Mus of WT
Skin, right side is IMQ mouse skin.
Fig. 3 .PPAR δ protein content in IMQ mice with WT mouse skin is expressed.
The apparent skin change of mice after Fig. 4 .GSK3787 treatment.In figure, a, b, c, d represent successively is empty
White group, IMQ group, GSK3787 group, clobetasol propionate positive treatment group.
The mice Pigs with Psoriasis that IMQ is induced by Fig. 5 .PPAR δ selective antagonist is at apparent and H&E
On therapeutical effect.In figure a, b, c, d represent successively be blank group, IMQ group, GSK3787 group,
Clobetasol propionate positive treatment group.
Detailed description of the invention
Below in conjunction with embodiment and accompanying drawing, the present invention is described in detail, but the enforcement of the present invention is not limited only to
This.
Agents useful for same of the present invention and raw material the most maybe can be prepared by literature method.Unless otherwise indicated,
Otherwise percentage ratio and number are calculated by weight.Wherein:
1. experiment material
1.1 experimental apparatus
The semi-automatic paraffin slicing machine of RM2245 (Leca)；Cubis analytical balance (Germany Sai Duolisi
Group)；Refiner (MB550/800, WIGGENS, Germany)；Digital display calibrator (precision 0.01mm,
Shanghai six Pedicellus et Pericarpium Trapae)；Real-time PCR instrument (Roche,480II)；Low-temperature and high-speed is desk-top
Centrifuge (420/420R, Hettich company of Germany), pipettor (0.25～1000 μ L, France Gilson).
1.2 experimental drugs and reagent
DMSO (Sigma-Aldrich, USA)；GSK 3787(Selleck Chemicals,USA)；
TRIZOL(promega,USA)；CDNA Reverse Transcription box (promega, USA)；Real-time quantitative
PCR reaction kit (promega, USA)；Acetone (analytical pure, Shandong YuWang Industry Co., Ltd)；
DEPC water (, Shanghai raw work aseptic without enzyme)；(analytical pure, in Zhengzhou, sky experimental apparatus has dehydrated alcohol
Limit company)；Isopropanol (analytical pure, Shandong YuWang Industry Co., Ltd)；Neutral formalin (4%, Wuhan
Bio tech ltd of Google)；Distilled water (laboratory is provided for oneself)；(Zhejiang Tianrui Pharmaceutical has normal saline
Limit company)；The graceful depilatory cream of common vetch (Reckitt Benckiser Co., Ltd).
1.3 laboratory animal
FVB/N JCL mice (20 ± 2) g, male and female half and half, all it is purchased from The 2nd Army Medical College laboratory animal
The heart.
Embodiment 1:PPAR δ and part thereof generate lipase alox8 psoriatic lesion and IMQ mice
Expression in skin
1. experimental technique
1.1PPAR δ expression in Healthy People skin and psoriatic lesion measures
Skin operation drawn materials is placed in 4% appropriate formaldehyde, after fixing 24h according to paraffin-embedded often
Rule step is propagandized.IHC is dyeed, by embedded paraffin section 5mm, dimethylbenzene washes away stone
After wax, make a return journey immobilization with ethanol gradient elution.Subsequently section is placed in citrate, microwave treatment.
Use serum as blocking antibody, incubated at room 30min afterwards, incubate with PPAR δ mono-is anti-in 4 DEG C after completing
Educate 10 hours.
1.2PPAR δ expression in WT mice and IMQ mouse skin measures
IHC experiment measures with above-mentioned 1.1PPAR δ expression in Healthy People skin and psoriatic lesion.Right
Detect in WB, sacrifice is taken its skin of back, clean 2 times in PBS after removing subcutaneous fat.
Extract total protein, after measuring protein content, run SDS-page electrophoresis, transferring film.Film is sealed with 5% defatted milk powder
After closing, shaking table shakes 70 revs/min, closes 90min.Film after closing is put into and is added one in hybridization bag
Resisting and hatch 90min, rear addition two is anti-hatches 90min.Used one resists and is: PPAR δ (U.S. Abcam) and
Alox8 (U.S. LSBio). band ECL shows.
Q-PCR detection method is as follows: extract total tissue RNA with Triol (U.S., invitrogen), with
After according to test kit description, mRNA is reversed to cDNA (U.S. promega).In Roche Lightcycler
GAPDH is detected with Q-PCR, the mRNA level in-site of alox8, PPARd on 480II machine.Data are relative
The method of relative Ct is used to calculate after GAPDH normalization.Primer sequence see table 1.
Table 1 primer sequence
F:forward forward primer；R:reverse downstream primer.
2. experimental result
2.1PPAR δ expression in Healthy People skin and psoriatic lesion
As seen from Figure 1, left side is Healthy People skin, and right side is psoriasis people's skin lesion, it is seen that PPAR δ exists
Expression in Healthy People skin is concentrated mainly on basal layer, then occurs in granular layer in psoriatic lesion,
Illustrate that the differentiation along with horn cell, the content of PPAR δ also can raise.
2.2PPAR δ expression in WT mice and IMQ mouse skin
In Fig. 2 visible, left side is WT mouse skin, and right side is IMQ mouse skin.WT mice
In skin, the expression ratio of PPAR δ is less, is mainly found in the granular cell of differentiation, and in IMQ skin lesion,
PPAR δ is not only expressed in granular cell, also can be found at basal layer.
From figure 3, it can be seen that compared with WT mice the up-regulated of PPAR δ in IMQ mice skin lesion, about
For 2.3 times in WT skin, Alox8 has then raised about 10 times.
In addition, we also use q-PCR technology to draw alox8 (a kind of PPAR δ endogenic ligand life
Become enzyme) and PPAR δ there is also statistical significance.Illustrate IMQ induction mouse skin and psoriasis skin
At damage, PPAR δ and part metabolic enzyme thereof have raised.
The mouse skin psoriasiform inflammation curative effect of embodiment 2:PPAR delta antagonist treatment IMQ induction is divided
Analysis
1. experimental technique
The preparation of 1.1GSK3787 solution
GSK3787 (Shanghai selleck company) is first pre-dissolved in DMSO, vortex, is dissolved in third then at room temperature
In ketone so that it is ultimate density is 5uM.Solution keeps in Dark Place in 4 DEG C, joins on every Mondays.
The preparation of 1.2IMQ induced mouse model and packet, administration
FVB/N JCL Mouse feeder one week is to adapt to environment.Before experiment, mouse back is taken off by 24h depilatory cream
Hair.GSK group before giving IMQ continuous 2 days gives GSK3787 at depilation position, 1 times/day.IMQ
Successive administration 6 days, 1 times/day, each 50mg.After last administration, sacrifice is drawn materials.Experiment
It is divided into blank group (vaseline group), model group (IMQ group), GSK3787 treatment group
(IMQ+GSK3787 group), clobetasol propionate positive treatment group (IMQ+CLO group).
1.3 efficacy analysis
After completing test by above-mentioned steps and packet, take the apparent picture of mouse back skin with camera, point
Analysis GSK is at the remission effect of the psoriasiform clinic pointer induced for IMQ.GSK is detected with H&E
Group is relative to IMQ group in morphologic change, and the histologic characteristics that observation psoriasis is correlated with is (such as epidermis
Prominent, acanthosis, parakeratosis etc.) change situation.
2. experimental result
2.1GSK3787 the apparent skin change of mice after Zhi Liao
Naive mice surface skin is smooth, without obvious psoriasiform squama；IMQ group mouse skin is visible
Significantly redden, there is substantial amounts of squama；GSK3787 group then can alleviate the phenomenon that IMQ group shows,
Its effect is close with clobetasol propionate positive treatment group.It is also seen that the clobetasol propionate positive is controlled from figure
The skin for the treatment of group mice is the reddest, (see Fig. 4) that this reason being likely due to hormone itself is caused.
Mouse skin morphological change after 2.2GSK3787 treatment
Naive mice epidermal thickness is less, without obvious psoriasiform pathological characteristics；IMQ group mice
H&E substantially thickens, it is seen that significantly acanthosis and trochanterellus；GSK3787 group then can alleviate IMQ group
The phenomenon showed, although its effect relatively clobetasol propionate positive treatment group is almost, but from figure
Can be seen that the skin histology of clobetasol propionate positive treatment group mice is loose, not as GSK3787 group more
Closely, this is likely due to what hormone itself was caused, sees Fig. 5.Compared to IMQ group, we can send out
The back psoriasiform phenomenon of existing GSK3787 treatment group mice to have obtained obvious improvement.Can from H&E
Drawing, compared to IMQ group, the histologic characteristics of GSK group to be very significantly improved, from epidermal proliferation
Rate can be seen that epidermal proliferation have also been obtained the biggest alleviation (p ＜ 0.01).
Below preferred embodiment to the invention is illustrated, but the invention does not limit
In described embodiment, those of ordinary skill in the art also may be used on the premise of the invention spirit
Making modification or the replacement of all equivalents, the modification of these equivalents or replacement are all contained in the application right and want
In seeking limited range.
Claims (10)
- The application in preparation treatment psoriasis of the 1.PPAR δ selective antagonist.
- PPAR δ selective antagonist the most according to claim 1 is in preparation treatment psoriasis Application, it is characterised in that described medicine is external preparation.
- PPAR δ selective antagonist the most according to claim 2 is in preparation treatment psoriasis Application, it is characterised in that described medicine be Emulsion, ointment, rubber plaster, colloid, membrane, Tincture, medicated wine, distillate medicinal water, sponginum, ionophore, or cutaneous permeable agent.
- 4. according to the arbitrary described PPAR δ selective antagonist of claim 1-3 at preparation treatment psoriasis Application in medicine, it is characterised in that described pharmaceutical pack contains one or more PPAR δ selectivitys Antagonist.
- PPAR δ selective antagonist the most according to claim 1 is in preparation treatment psoriasis Application, it is characterised in that described PPAR δ selective antagonist is GSK3787.
- PPAR δ selective antagonist the most according to claim 5 is in preparation treatment psoriasis Application, it is characterised in that described medicine is using GSK3787 as sole active composition.
- PPAR δ selective antagonist the most according to claim 6 is in preparation treatment psoriasis Application, it is characterised in that in described medicine, the concentration of GSK3787 is 5uM.
- 8. treat psoriatic medicine for one kind, it is characterised in that the described activity treating psoriatic medicine Composition is PPAR δ selective antagonist.
- The psoriatic medicine for the treatment of the most according to claim 8, it is characterised in that described treatment silver The active component of the medicine that bits are sick is GSK3787.
- 10.PPAR δ application in screening treatment psoriasis, described medicine is that PPAR δ is short of money Anti-agent or inhibitor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610344938.4A CN105998015A (en) | 2016-05-23 | 2016-05-23 | Application of PPARdelta (Peroxisome proliferator-activated receptor delta) selective antagonist in preparation of drugs for treating psoriasis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610344938.4A CN105998015A (en) | 2016-05-23 | 2016-05-23 | Application of PPARdelta (Peroxisome proliferator-activated receptor delta) selective antagonist in preparation of drugs for treating psoriasis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105998015A true CN105998015A (en) | 2016-10-12 |
Family
ID=57095790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610344938.4A Pending CN105998015A (en) | 2016-05-23 | 2016-05-23 | Application of PPARdelta (Peroxisome proliferator-activated receptor delta) selective antagonist in preparation of drugs for treating psoriasis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105998015A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107028949A (en) * | 2017-05-25 | 2017-08-11 | 瑞阳制药有限公司 | Nintedanib is used to treat the purposes in the external preparation medicine of psoriasis |
| CN107519482A (en) * | 2017-10-10 | 2017-12-29 | 中国人民解放军第四军医大学 | A kind of interleukin 28 A is as the application prepared in treatment psoriasis |
| CN112190708A (en) * | 2019-07-08 | 2021-01-08 | 上海交通大学医学院附属瑞金医院 | Novel use of chemokine receptor CCR6 inhibitors for preventing psoriasis recurrence |
-
2016
- 2016-05-23 CN CN201610344938.4A patent/CN105998015A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| KATRIN HACK等: "Skin-Targeted Inhibition of PPAR β/δ by Selective Antagonists to Treat PPAR β/δ-Mediated Psoriasis-Like Skin Disease In Vivo", 《PLOS ONE》 * |
| XUGUO WANG等: "A PPARδ-selective antagonist ameliorates IMQ-induced psoriasis-like inflammation in mice", 《INTERNATIONAL IMMUNOPHARMACOLOGY》 * |
| 庞晓文 等: "过氧化物酶体增殖物激活受体在寻常性银屑病患者表皮中的表达", 《中华皮肤科杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107028949A (en) * | 2017-05-25 | 2017-08-11 | 瑞阳制药有限公司 | Nintedanib is used to treat the purposes in the external preparation medicine of psoriasis |
| CN107519482A (en) * | 2017-10-10 | 2017-12-29 | 中国人民解放军第四军医大学 | A kind of interleukin 28 A is as the application prepared in treatment psoriasis |
| CN112190708A (en) * | 2019-07-08 | 2021-01-08 | 上海交通大学医学院附属瑞金医院 | Novel use of chemokine receptor CCR6 inhibitors for preventing psoriasis recurrence |
| CN112190708B (en) * | 2019-07-08 | 2023-09-05 | 上海交通大学医学院附属瑞金医院 | Novel use of chemokine receptor CCR6 inhibitors for preventing psoriasis recurrence |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrews et al. | Wound management of chronic diabetic foot ulcers: from the basics to regenerative medicine | |
| Guo et al. | Licochalcone A protects the blood–milk barrier integrity and relieves the inflammatory response in LPS-induced mastitis | |
| Gao et al. | Mesenchymal stromal cell-conditioned medium prevents radiation-induced small intestine injury in mice | |
| JP6900358B2 (en) | Cell-free composition for cell restoration and method of preparation and use of the same composition | |
| JP2021169449A (en) | microRNA COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME | |
| WO2019024758A1 (en) | Application of glycoside compound in preparing drug for treating hepatic fibrosis | |
| Fan et al. | Effects and mechanism of action of Huang-Lian-Jie-Du-Tang in atopic dermatitis-like skin dysfunction in vivo and in vitro | |
| CN103948575A (en) | Application of cinnamyl aldehyde in preparing medicament for promoting angiogenesis | |
| CN103285155B (en) | Traditional Chinese medicine composition for treating eczema and dermatitis | |
| CN105998015A (en) | Application of PPARdelta (Peroxisome proliferator-activated receptor delta) selective antagonist in preparation of drugs for treating psoriasis | |
| Romagnoli et al. | Clinical evaluation of intralesional injection of platelet-rich plasma for the treatment of proximal suspensory ligament desmitis in horses | |
| Hao et al. | Effects of hyperbaric oxygen therapy on the expression levels of the inflammatory factors interleukin-12p40, macrophage inflammatory protein-1β, platelet-derived growth factor-BB, and interleukin-1 receptor antagonist in keloids | |
| Yu et al. | SQSTM1/p62 promotes cell growth and triggers autophagy in papillary thyroid cancer by regulating the AKT/AMPK/mTOR signaling pathway | |
| Cequier et al. | The usefulness of mesenchymal stem cells beyond the musculoskeletal system in horses | |
| Cheng et al. | Fuzheng Huayu inhibits carbon tetrachloride-induced liver fibrosis in mice through activating hepatic NK cells | |
| Ding et al. | Mesenchymal stem/stromal cells primed by inflammatory cytokines alleviate psoriasis-like inflammation via the TSG-6-neutrophil axis | |
| Zhang et al. | Glycyrrhizin alleviates Con A-induced hepatitis by differentially regulating the production of IL-17 and IL-25 | |
| CN105853421A (en) | Novel application of FoxO1 selective inhibitor AS1842856 | |
| Ru-Zhi et al. | Two uncommon cases of idiopathic atrophoderma of pasini and pierini: multiple and giant | |
| CN107441071B (en) | A kind of application of ar-turmerone in preparation treatment and/or prevention psoriasis | |
| Wang et al. | Perihematomal endothelin-1 level is associated with an increase in blood-brain barrier permeability in a rabbit model of intracerebral hematoma | |
| US20170014484A1 (en) | Methods of Promotion of Healing of Diabetic Wounds | |
| CN108578683A (en) | Application of the Liraglutide in curing psoriasis drug and in diabetes B merges curing psoriasis drug | |
| Huang et al. | Effects of ischemic post-conditioning on the expressions of LC3-II and Beclin-1 in the hippocampus of rats after cerebral ischemia and reperfusion | |
| Caruso et al. | Pathogenic role of interleukin-21 in psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |
|
| RJ01 | Rejection of invention patent application after publication |